Show simple item record

dc.contributor.authorSmrke, Aen_US
dc.contributor.authorYounger, Een_US
dc.contributor.authorWilson, Ren_US
dc.contributor.authorHusson, Oen_US
dc.contributor.authorFarag, Sen_US
dc.contributor.authorMerry, Een_US
dc.contributor.authorMacklin-Doherty, Aen_US
dc.contributor.authorCojocaru, Een_US
dc.contributor.authorArthur, Aen_US
dc.contributor.authorBenson, Cen_US
dc.contributor.authorMiah, ABen_US
dc.contributor.authorZaidi, Sen_US
dc.contributor.authorGennatas, Sen_US
dc.contributor.authorJones, RLen_US
dc.date.accessioned2020-07-15T14:58:05Z
dc.date.issued2020-07en_US
dc.identifier.citationJCO global oncology, 2020, 6 pp. 1046 - 1051en_US
dc.identifier.issn2687-8941en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3846
dc.identifier.eissn2687-8941en_US
dc.identifier.doi10.1200/go.20.00220en_US
dc.description.abstract<h4>Purpose</h4>Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, including rapid adoption of telemedicine-based care. We aimed to evaluate the impact of telemedicine on patients, clinicians, and care delivery at the Royal Marsden Hospital (RMH) Sarcoma Unit during the pandemic.<h4>Methods</h4>Data were extracted from patient records for all planned outpatient appointments at the RMH Sarcoma Unit from March 23 to April 24, 2020. Patients and clinicians completed separate questionnaires to understand their experiences.<h4>Results</h4>Of 379 planned face-to-face appointments, 283 (75%) were converted to telemedicine. Face-to-face appointments remained for patients who needed urgent start of therapy or performance status assessment. Patients lived on average > 1.5 hours from RMH. Patient satisfaction (n = 108) with telemedicine was high (mean, 9/10), and only 48% (n = 52/108) would not want to hear bad news using telemedicine. Clinicians found telemedicine efficient, with no associated increased workload, compared with face-to-face appointments. Clinicians indicated lack of physical examination did not often affect care provision when using telemedicine. Most clinicians (n = 17; 94%) believed telemedicine use was practice changing; congruently, 80% (n = 86/108) of patients desired some telemedicine as part of their future care, citing reduced cost and travel time.<h4>Conclusion</h4>Telemedicine can revolutionize delivery of cancer care, particularly for patients with rare cancers who often live far away from expert centers. Our study demonstrates important patient and clinician benefits; assessment of longer-term impact on patient outcomes and health care systems is needed.en_US
dc.formatPrinten_US
dc.format.extent1046 - 1051en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectPneumonia, Viralen_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectSarcomaen_US
dc.subjectGastrointestinal Neoplasmsen_US
dc.subjectSoft Tissue Neoplasmsen_US
dc.subjectGastrointestinal Stromal Tumorsen_US
dc.subjectAmbulatory Careen_US
dc.subjectRetrospective Studiesen_US
dc.subjectMedical Oncologyen_US
dc.subjectTelemedicineen_US
dc.subjectTravelen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectMiddle Ageden_US
dc.subjectWorkloaden_US
dc.subjectPatient Satisfactionen_US
dc.subjectDelivery of Health Careen_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.subjectYoung Adulten_US
dc.subjectPandemicsen_US
dc.subjectUnited Kingdomen_US
dc.subjectBetacoronavirusen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.titleTelemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1200/go.20.00220en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2020-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJCO global oncologyen_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublisheden_US
pubs.volume6en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamClinical and Translational Sarcomaen_US
icr.researchteamAetiological Epidemiologyen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorZaidi, Shane Haideren_US
dc.contributor.icrauthorMacklin-Doherty, Aislinnen_US
dc.contributor.icrauthorHusson, Olgaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/